Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seagen Inc
(NQ:
SGEN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seagen Inc
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Embattled Biotech Seagen Rockets On Rumors Merck Could Buy It
June 17, 2022
The rumor emerges shortly after the company's former CEO was arrested.
Via
Investor's Business Daily
Merck Shows Takeover Interest In Seagen: WSJ
June 17, 2022
Via
Benzinga
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
June 16, 2022
Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 12.54% on an annualized basis producing an average annual return of 19.38%. Currently, Seagen has a market capitalization of...
Via
Benzinga
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
June 13, 2022
Via
Benzinga
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
June 06, 2022
From
Seagen Inc.
Via
Business Wire
Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence
May 09, 2022
Via
Benzinga
Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim
May 09, 2022
Siegall says he is going through a divorce and denied the claim.
Via
Investor's Business Daily
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
June 06, 2022
From
Genmab A/S
Via
Business Wire
10 Biggest Price Target Changes For Monday
June 06, 2022
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.
Via
Benzinga
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
June 03, 2022
From
Seagen Inc.
Via
Business Wire
Expert Ratings for Seagen
April 29, 2022
Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings:
Via
Benzinga
5 Growth Stocks to Buy Now
May 27, 2022
EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks.
Via
InvestorPlace
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
May 23, 2022
Via
Benzinga
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
May 23, 2022
From
Seagen Inc.
Via
Business Wire
Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest
May 16, 2022
Clay Siegall and the board agreed it would be in investors' best interest if he resigned.
Via
Investor's Business Daily
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
May 16, 2022
From
Seagen Inc.
Via
Business Wire
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
May 16, 2022
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.
Via
Talk Markets
103 Biggest Movers From Yesterday
May 11, 2022
Gainers
Via
Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
Gainers
Via
Benzinga
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
May 09, 2022
From
Seagen Inc.
Via
Business Wire
Looking Into Seattle Genetics's Return On Capital Employed
May 04, 2022
According to Benzinga Pro data, during Q1, Seattle Genetics (NASDAQ:SGEN) posted sales of $426.46 million. Earnings were up 21.84%, but Seattle Genetics still reported an overall loss of $136.49...
Via
Benzinga
4 Healthcare Funds With "Double Discounts"
April 30, 2022
There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look...
Via
Talk Markets
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
April 29, 2022
Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.
Via
Benzinga
Recap: Seagen Q1 Earnings
April 28, 2022
Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by...
Via
Benzinga
Seagen Reports First Quarter 2022 Financial Results
April 28, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 28, 2022
From
Seagen Inc.
Via
Business Wire
Earnings Scheduled For April 28, 2022
April 28, 2022
Companies Reporting Before The Bell • PBF Energy (NYSE:PBF) is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion.
Via
Benzinga
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
April 20, 2022
From
Seagen Inc.
Via
Business Wire
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
April 13, 2022
The
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.